Introduction
Werner syndrome (WS:MIM#27770) is an autosomalrecessively inherited disease caused by the mutation of RecQ3 helicase (WRN) located at chr8p11-12 (1) (2) (3) . WS patients are usually paid no special attention either from the family members or doctors concerning to any developmental abnormality until the usual premature termination of the teenage growth spurt and voice changes, followed by the age-related pathophysiology mimicking advanced aging (4) . WS has been classified as an adult form of progeria, the representative natural model for human aging, a caricature of human aging, or as a segmental progeroid syndrome (4) (5) (6) (7) . The clinical manifestations recognized in WS, irrespective of ethnic origin, are commonly scheduled by hierarchical deterioration of the connective tissue system, the endocrine-metabolic system, and later to lesser degree the immune system, and the central nervous system (4, 5) . Like other helicases, the intact WRN helicase functions at the time of cell proliferation/division inside the mitotic cells, while the mutated/truncated WRN helicase protein does not (8) (9) (10) . Thus, the systems/organs mainly consisting of post-mitotic cells like central nervous system and cardiac muscles may have at the most minor changes in WS. Actually no apparent association has been reported in WS with Alzheimer disease, Parkinson disease, and cardiomyopathy that may be frequently observed in elderly general population.
Since the first description of WS by Otto Werner in 1904 (11) , additional WS case reports have accumulated worldwide, the majority being from Japan (4, 12) . So, we would like to review the details of the up-dated information written in Japanese to the non-Japanese readers (13) .
Database
In the series of the previous reports, the literature has been searched for publications on WS through a citation index in and out of Japan between 1904 and 1995 (3, 4, 14, 15 (3, 4, 14, 15) : i) Characteristic habitus and stature:short stature and light body weight, slender extremities with stocky trunk and beak-shaped nose. ii) Premature senescence:bird-like appearance, alopecia/gray hair, skin hyperpigmentation, hoarseness, diffuse arteriosclerosis, juvenile bilateral cataracts and osteoporosis. iii) Scleroderma-like skin changes:atrophic skin and muscle, circumscribed hyperkeratosis, telangiectasia, tight skin over bones of feet, skin ulcers and localized calcification. iv) Endocrine-metabolic abnormalities: diabetes mellitus (DM) and hypogonadism. Diagnosis of neoplasia was as given by the original authors.
Approximately 200 Japanese WS patients (WS0101-WS60001) diagnosed by our criteria were further confirmed by the loss of intact WRN protein and the presence of WRN mutations as previously reported (3, 16, 17) . B-lymphoblastoid cells and skin fibroblasts from ~200 WS patients and their family members are deposited at RIKEN Bio-Resource Center (Tsukuba Japan) as Goto Collection of Werner Syndrome and can be used by researchers upon request (http://biolod.org/ class/cria304u12i/Goto_Collection_EBV_transformed_ B_cell_lines_ and_primary_fibroblast_derived_from_ Werner_syndrome_patient).
Brief history of clinical characterization of Werner syndrome
The history of WS research begins with the publication of a doctoral dissertation by a German general physician (later an ophthalmologist) at the University of Kiel in 1904, Otto Werner (11). He described several progeric manifestations, in addition to skin sclerosis and bilateral juvenile cataracts. Werner carefully differentiated the clinical manifestations in his patients from those with similar phenotypic manifestations formerly described by Rothmund (18) , later known as Rothmund-Thomson syndrome (RTS: MIM#26840; [18] [19] [20] . Interestingly, we found the mutation of RecQ4 (RECQL4) located at chr 8p24.3, belonging to the same RecQ helicase family as WS causes RTS (21) .
In Japan, Ishida, an ophthalmologist in Kyoto University, reported the first probable Japanese case of WS in 1917 (22) , followed by a continuous publication of Japanese cases up to 1,128, while a total of 359 outside of Japan at the end of 2008 (Figure 1) (4,12,23) . The number of patients associated with malignancy (between 1907 and 2008) was shown in the parentheses within the table in Figure 1 .
Thirty years later from Werner's original observation, the door to WS research was reopened by two New York internists, Kugel, in 1934 and 1941 (24,25) . They coined the name: "Werner's syndrome" and published the first necropsy case. The first reference of the rare malignancy in WS, fibroliposarcoma, was reported by Agatson and Gartner in 1939 (23,26) . A Boston internist, Thannhauser reviewed WS and RTS as the discrete syndromes in 1945 (20) , and Seattle-based geneticist group, Epstein et al. released a landmark overview on 125 cases of WS including 8 Japanese cases in 1966 (5) .
Since the Ishida's first case report, the first necropsy Japanese WS case was documented in 1966 by Hamada (27) , followed by the first association case report of WS with malignancy: malignant melanoma in 1968 by primary/secondary hypogonadism, thyroid hyper/hypodysfunction, hyperuricemia and hyper-lipidemia; 80% at age 35 years old)
The frequency of DM among Japanese WS patients has been constant in contrast to the rapid increase among general Japanese population. Of particular interest, the age at onset of DM in WS has delayed (12 (12, 33, 37) , though all the WS patients showed an intravisceral fat accumulation revealed by MRI examination (33, 38) .
The serum adiponectin level decreased and the TNFα level increased in diabetic patients in general. In WS, adiponectin was significantly suppressed and TNFα is significantly enhanced compared with the controls. In addition, treatment of DM by pioglitazone normalized adipocytokines in WS (38) . Recently, the WS patients associated with NASH (non-alcoholic steatohepatitis) have been reported (39) .
Hypogonadism from both sexes was observed in 40%. Of special interest, one of the most prominent features in normal elderly male: prostate hypertrophy has never been recognized in WS. The thyroid dysfunction either of hyper-, hypo-function or malignancy that had been observed in the ~15% among WS patients has been rarer (15) . All types of hyperuricemia were found in 10% in WS, though hyperuricemia was not usually associated with normal aging (40) . Some patients had a history of gouty attack (41) . Hyperlipidemia, characterized by hypertriglyceridemia was still a biochemical hallmark of WS (4, 37) .
The pathogenetical concept of atherosclerosis has been changing, though hyperlipidemia is still a risk factor for atherosclerosis. Atherosclerosis has been viewed as a sort of 'silent auto-inflammation' caused by the proinflammatory cytokines produced by macrophages that phagocytose modified lipoprotein particles (42) . Interestingly, one autopsy case of 51 years old female WS patient who neither had dyslipidemia nor DM showed mild atherosclerosis similar to her age (43) . She died of myelodysplastic syndrome (MDS).
Since the first description by Tokunaga et al., the elevation of hyaluronan both in the urine and the serum has been constantly reported in WS. WS has been formerly inadvertently classified as a new group of hereditary mucopolysaccharidosis (44) (45) (46) . Hyaluronan elevation either from urine and serum has been believed as a biomarker of normal aging and progeroid syndromes such as WS and progeria (46) (47) (48) (49) and the International Registry of Werner syndrome included hyaluronuria for diagnosing WS (http://www. pathology. washington.edu/ research/werner/registry/ diagnostic.html). However, the excessive production Koga (23, 28) . We proposed in 1981 for the first time the initial screening criteria for the possible WS patient as described (3, 4, 14, 15) .
Changing clinical manifestations
4.1. Characteristic bird-like appearance and body habitus (100% at age 35 years) Short stature, light body weight, and stocky trunk with extremely thin extremities were noted in all the patients at age 26 years old. These characteristic appearance including bird-like faces, extremities mimicking Cushing syndrome or Klinefelter syndrome is still a hallmark of WS (4, 12, 14) . Body size (height: 122-161 cm and weight: 19-52 kg) is also still small, but has been expanding in concert with the growing constitution in general Japanese population. Some patients exceeded 177 cm high and weighed over 70 kg.
Premature senescence (100% at age 35 years)
Gray hair/alopecia, bilateral cataracts, hoarseness, osteoporosis with osteosclerosis, and atherosclerosis are the hallmarks of WS. Interestingly, osteoporosis is usually more pronounced in postmenopausal women than men in general population, but this is not the case in WS. WS men have severer osteoporosis, either peripheral or vertebral, than women (29, 30) . Osteoarthritis, one of the commonest features in a general elderly population, has not been frequently reported in WS (31).
Scleroderma-like skin changes (100% at age 35 years)
Skin atrophy, skin sclerosis, skin ulcers, hypo/hyperpigmentation, telangiectasia, sarcopenia, subcutaneous calcification, painful corns, and flat feet were included. Skin sclerosis such as extremely tight skin over malleoli and painful corns: the historical hallmark of WS has been rarer recently, though the reason is unknown. The skin ulcers in WS especially of lower extremities were induced by the daily mechanical stress in combination with the decreased cellular replicative potential and the subcutaneous fat defect (14, 32, 35, 36) . The skin ulcers in WS have been still well-known as the most incurable and occasionally leading to the amputation of the legs resulted from gangrene among dermatologists and orthopedic surgeons. Neither skin ulcers nor subcutaneous calcifications is usually associated with natural aging. Approximately 25% WS patients escape from skin ulcers (32,35). As described above, subcutaneous calcification, especially along the Achilles tendon is the must for diagnosing WS (36) . So-far, all the mutation-proven WS have the Achilles tendon calcification, although relatively mild in some cases 4.4. Endocrine-metabolic disorders (type II DM, of hyaluronan has been widely reported in other inflammatory conditions such as rheumatoid arthritis and liver diseases (50) (51) (52) . The increased serum/urine hyaluronan level in aging and WS has been recognized as the result from chronic inflammation (48, 49, 53, 54) .
Immune system disorders
Immune system has been believed as the most sensitive organ to normal aging (55) (56) (57) (58) (59) (60) . At the age of 35 years, Approximately 80% of the WS patients show signs of mild immune abnormalities. A deficiency in sofar unidentified T cell subsets similar to the healthy nanogerian was detected in WS (56) . Decreased natural killer cell activity, which recovered after the interferon stimulation, was observed in most WS patients (57) . Most patients had low titers of several autoantibodies, including IgG anti-double-stranded DNA antibody, antinuclear antibody, and rheumatoid factor, as is usually observed in the healthy population over the age of 60 years (58, 59) . The autoantibody specific to autoimmune systemic sclerosis: anti-topoisomerase I (Scl-70), has never been detected in WS, although antinucleolar antibody of an undefined type was detected in some cases (59, 60) . Interestingly, a small percentage of the patients had autoimmune diseases, including Graves' disease, systemic lupus erythematosus, Sjogren's syndrome, and autoimmune hepatitis (60) . However, WS patients were not abnormally sensitive to bacterial or viral infection at any stage of their life, even though the third major cause of death in WS is bacterial pneumonitis similar to the general Japanese population (4). The various types of low titer of auto-antibody production have been presumed as the result from the imbalance between inflammatory/anti-inflammatory responses against natural/modified antigens.
We have proposed the sub-normal immune system in WS may induce 'silent inflammation', 'inflammaging', or para-inflammation normally responsive to the daily infectious attacks and persistent oxidative stress, leading to the pathophysiology of DM, atherosclerosis, malignancy, auto-antibody production, and hyaluronan production (48,50,52-54,61).
4.6.
Nervous system disorders (frequency: 40% at age 35) WS has been believed to have a relatively normal central nervous system, consisting of mainly postmitotic cells that may escape from WRN helicase dysfunction (62) . However, with the recent advance of medical devices including computed tomography and magnetic resonance imaging (MRI), brain atrophy has been observed in 40% of WS patients, even before the age of 40 years (4, 63, 64) . At least 3 WS patients had senile dementia due to subcortical arteriosclerotic encephalopathy or multiple meningioma, but not of the Alzheimer type by clinical determination and autopsy (65) (66) (67) . Of great interest, 10% patients had schizophrenia of paranoia type at the age of ~37 years (4). Either bipolar or monopolar mood disorder has been rare in WS (68) . Although ~10% WS had hearing loss as a result of otitis media infection and ~15% mental retardation before 1970, both symptoms have never been reported recently.
Changing pattern of malignancy
The average age of onset of malignancy in WS was 36.9 years old in 1966, while 48.8 years old in 2004 and 48.9 years old in 2008. As already reported, nonepithelial neoplasms including soft-tissue sarcoma (STS), osteosarcoma, malignant melanoma, benign meningioma, and myeloid disorders are still a hallmark of WS as listed in Table 1 (23) . WS has been classified as a member of hereditary cancer-prone syndrome. The ratio of epithelial to non-epithelial cancers was about 1:1.5 instead of the usual 10:1. Thyroid carcinoma and malignant melanoma have been frequently associated with Japanese WS as was reported (69) . Among epithelial neoplasms three WS were associated with pulmonary carcinoma that has never been reported before (23) , though neither additional prostatic nor colorectal carcinoma has been reported as shown in Table 1 .
Multiple primary neoplasms or myeloid disorders are also a hallmark in WS (Table 2) (23) . Twenty five Japanese with WS had primary neoplasms, or neoplasia with MDS. Thyroid carcinoma, malignant melanoma, meningioma, MDS, and MFH (malignant fibrous histiocytoma) were the frequent counterpart in the multiple primary neoplasms. Of note, six primary neoplasms were found in a Japanese man with possible WS, though the WRN mutation in the patient was not examined (70).
Genetics

Geographical distribution and mutation type
WS is a genetic disease transmitted by autosomally recessive inheritance (14) . Although consanguineous marriage especially in rural areas may still contribute the relatively high incidence of WS in Japan, consanguinity (mostly first-cousin marriage) was noted in only ~45% among ~200 mutation-proven WS patients. In addition, familial occurrence has been infrequent since 1996. Most cases recently reported are sporadic. The patients have been reported from all area of Japan and outside of Japan (Figure 1 ), while there are still several clustering areas in Japan as have been already reported (4, 14, 71) .
Since the discovery of WRN gene in 1996 (2), the mutation type of the responsible gene:WRN has been reported in and outside of Japan. According to the International Registry of Werner syndrome (http://www. pathology.washington.edu/research/werner/registry/ diagnostic. html), the number of the mutation type has accumulated up to ~100 worldwide. Approximately 200 Japanese WS patients (WS0101-WS61901) diagnosed by our criteria were further confirmed by the loss of intact WRN protein and the presence of WRN mutations (3, 16, 17) . Although the precise mutation in ~15% patients with defective WRN protein is not identified yet, the mutation types so-far recognized in Japan are quite different from those outside Japan as shown in Table 3 . Interestingly, the majority of the Japanese patients with WS have mutation type 4, that has never been found in the non-Japanese WS.
Japan is the largest producer of WS (4,14,71), probably because of an extremely high incidence (1:100) of heterozygous carriers in Japan (14, 71, 72) . Although few patients with WS have been reported in ethnically similar Asian countries such as Korea, the incidence of heterozygous carriers in general population in the representative 3 areas of Korea (Seoul, Pusan, and Gwangju) was less than 1:1,000 (73, personal communication from Drs. F. Takeuchi and A. Park).
Changing pattern of longevity
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Does early pathophysiology determine the life-span?
Analyses of the way how aging-related conditions may rapidly arise in WS may give us the fundamental insight into the pathophysiological mechanisms of human aging. Since the most clinical manifestations characteristic in WS usually overlap with those of natural aging process at an early stage of life, most patients, family members and even doctors do not acknowledge the presence of the disease before the age of 36.7 ± 10.1 years (4), even if additional family members are already recognized as affected. The parents of children with WS may in some time recognize the abnormality either by their lack of the prepubertal growth spurt, the loss of sex maturation and voice change or the early onset of cataract. Reliable records, particularly of early pathophysiological manifestations of WS, are therefore limited. As listed in Table 4 , we examined in mutation-proven WS; i) if longer lifespan (age > 63years) was linked with slower progeroid outcomes (age < 40years), and ii) if earlier onset of clinical symptoms (age < 13years) was associated with a shorter life-span (age < 40years). These results may suggest a possible common environmental/epigenetical link between the longevity in WS and the general population (12) .
Several long-lived patients (age > 63 years old) were not diagnosed with WS prior to 35 years of age. In a few patients who had shorter life-spans of age < 40 years, premature aged phenotypes typical of WS before age 10 were noted. The percentage of WS patients suffering from early death at < 40 years of age was 34.9% prior to 1985, and 13.3% after 1986 for both sexes. There was no significant difference between males and females in the frequency of early death. The major causes of death in WS have been malignancy, acute myocardial infarction (AMI) and infection; similar to the general population.
Thus, although data is limited, there appears to be no clear-cut correlation between delayed onset of WSspecific progeroid symptoms and a longer life-span or vice versa.
Family analysis: Does WRN heterozygote contribute longevity?
The longevity (> 90 years old) members have been sometimes encountered among heterozygous carriers in WS families as listed in Table 5 .
Although the data is still limited and we do not know if WRN heterozygosity may contribute longevity, WRN has been recently reported to modulate mitochondrial ROS (reactive oxygen species) production by the repression of HIF-1 (hypoxia inducible factor-1) activity (76) . So, the 50% WRN function may moderately suppress ROS production leading to longevity. Obviously, this notion is highly speculative and further study may be required.
Conclusion
We should bear in mind that as the rapid improvement and changes in the average life-span and life-style in general population all over the world, the life-span and clinical manifestations even in the geneticallydetermined disease like WS may change extensively as already described (12) . This may suggest the possible interventional treatment for the clinical changes in WS, age-related diseases in the general population and even pathophysiology of natural aging.
Although the recent delayed onset of typical progeroid phenotypes in WS caused by the loss of function of WRN may be explained by the environmental changes including life-style and medical improvement, genes normally cooperated with WRN may possibly contribute unexpected phenomenon . While this notion is highly speculative, the in vitro molecular studies and the prospective cohort study by using the larger number of mutation-proven Japanese patients may allow direct testing of these concepts in the future.
